(VIANEWS) – Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) dropped 9.06% to $713.34 at 16:08 EST on Tuesday, following the last session’s upward trend. NASDAQ is jumping 1.72% to $13,565.66, after two consecutive sessions in a row of losses. This seems, so far, an all-around bullish trend trading session today.
Regeneron Pharmaceuticals’s last close was $784.38, 6.35% below its 52-week high of $837.55.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $37.02.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 19.27. Meaning, the purchaser of the share is investing $19.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.27%.
Volume
Today’s last reported volume for Regeneron Pharmaceuticals is 1775613 which is 237.18% above its average volume of 526598.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 4.3% and a drop 1.7% for the next.
Yearly Top and Bottom Value
Regeneron Pharmaceuticals’s stock is valued at $713.34 at 16:08 EST, way under its 52-week high of $837.55 and way above its 52-week low of $563.82.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Regeneron Pharmaceuticals’s EBITDA is 6.41.
More news about Regeneron Pharmaceuticals (REGN).
